EyePoint Pharmaceuticals
Biotechnology-Research
Website
Company Tagline
Delivering Innovation to the Eye™ NOW HIRING!
Industry Category
Business Keywords
Company Description
EyePoint Pharmaceuticals is dedicated to enhancing the lives of patients suffering from serious eye disorders through the development and commercialization of innovative therapeutics. Located in Watertown, Massachusetts, EyePoint Pharmaceuticals leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create groundbreaking treatments. Their leading product, EYP-1901, is a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is committed to advancing eye care and providing effective solutions for patients in need.
EyePoint Pharmaceuticals' proven Durasert® intravitreal drug delivery platform has a strong track record, having been safely administered to thousands of patients' eyes via four U.S. FDA-approved products. One such product is YUTIQ®, used for treating chronic non-infectious uveitis affecting the posterior segment of the eye, and currently marketed by EyePoint Pharmaceuticals. The company’s focus on research and development ensures a continuous pipeline of innovative treatments that address critical needs in ophthalmology. EyePoint Pharmaceuticals is located at 480 Pleasant St., Suite B300, Watertown, MA 02472, US.
EyePoint Pharmaceuticals continues to be a leader in the biotechnology research field, focusing on innovation and patient care. The company is dedicated to expanding its portfolio and improving treatment options for a variety of eye conditions. We invite the manager of EyePoint Pharmaceuticals to create a customized and exclusive company showcase and product listing on our platform, further highlighting their contributions to the field.
EyePoint Pharmaceuticals se consacre à l'amélioration de la vie des patients souffrant de troubles oculaires graves grâce au développement et à la commercialisation de traitements thérapeutiques innovants. Située à Watertown, dans le Massachusetts, EyePoint Pharmaceuticals tire parti de sa technologie exclusive Durasert®, un système d'administration intraoculaire prolongée de médicaments, pour créer des traitements révolutionnaires. Leur produit phare, EYP-1901, est un traitement anti-VEGF intravitréen potentiel de six mois ciblant initialement la dégénérescence maculaire liée à l'âge de forme humide. EyePoint Pharmaceuticals s'engage à faire progresser les soins oculaires et à fournir des solutions efficaces aux patients qui en ont besoin.
La plateforme éprouvée d'administration intraoculaire de médicaments Durasert® d'EyePoint Pharmaceuticals possède une solide expérience, ayant été administrée en toute sécurité aux yeux de milliers de patients via quatre produits approuvés par la FDA aux États-Unis. L'un de ces produits est YUTIQ®, utilisé pour traiter l'uvéite chronique non infectieuse affectant le segment postérieur de l'œil, et actuellement commercialisé par EyePoint Pharmaceuticals. L'accent mis par l'entreprise sur la recherche et le développement assure un pipeline continu de traitements innovants qui répondent aux besoins essentiels en ophtalmologie. EyePoint Pharmaceuticals est située au 480 Pleasant St., Suite B300, Watertown, MA 02472, États-Unis.
EyePoint Pharmaceuticals continue d'être un leader dans le domaine de la recherche biotechnologique, en se concentrant sur l'innovation et les soins aux patients. L'entreprise se consacre à l'expansion de son portefeuille et à l'amélioration des options de traitement pour diverses affections oculaires. Nous invitons le responsable d'EyePoint Pharmaceuticals à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme, mettant ainsi davantage en valeur leurs contributions dans le domaine.
Key Personnel / Employees
Compare Companies Side by Side
Compare EyePoint Pharmaceuticals with 3 companies in Biotechnology-Research
| Comparison Field |
EyePoint PharmaceuticalsMain Company |
NewmedicaView Profile |
Vision OptiqueView Profile |
Tenpoint Therapeutic...View Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 0 | 1999 | 2019 |
|
Company Size
|
— | 51-200 | 11-50 | 51-200 |
|
City
|
Watertown, MA | London, Greater London | Houston, TX | Irvine, California |
|
Country
|
United States | United Kingdom | United States | United States |
|
Skills & Keywords
Comparing with main company
|
11 Total Skills
Biotechnology
Pharmaceuticals
Ophthalmology
Eye Care
Drug Delivery
Retinal Disease
Macular Degeneration
WetAMD
Eye Disease
Optometry
Glaucoma
|
2 Total
2 Unique
Unique Skills:
Cataract Surgery
Cataracts
|
12 Total
1 Common
11 Unique
Match
9%
Common Skills:
Macular Degeneration
Unique Skills:
Anti-Aging Eye Care
Diabetes
Digital Eye Health
Double Vision Solutions
Dry Eye
High End Frame Collections
+5
|
7 Total
7 Unique
Unique Skills:
AMD
dry eye disease
Eye Health
macular degeneration
ocular surface disease
Presbyopia
+1
|
4
Total Companies1999
Oldest Founded2
Countries30
Unique SkillsSimilar Companies
Other organizations in the same industry
GlucoSense Inc
Biotechnology-ResearchHelping Type 1 & Type 2 Diabetics Live Healthier, Stress-free Lives.
Stealth Biotech Development
Biotechnology-ResearchA strategic approach adopted by a company to keep its activities, products, or services confidential...
Alternative Company Names
This company is also known as